Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × binimetinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 15 Lung Neoplasms 10 Neoplasms 2 Neoplasm Metastasis 2 Melanoma 2 Colorectal Neoplasms 2 Thyroid Neoplasms 1 Solid Tumor 1 Recurrence 1 Pancreatic Neoplasms 1 Noonan Syndrome 5 1 Neurofibromatosis 1 1 Leukemia, Myeloid, Acute 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Glioma 1 Disease Progression 1 Central Nervous System Neoplasms 1 Carcinoma 1 Brain Neoplasms 1 Brain Diseases 1 Adenocarcinoma of Lung 1

Interventions

Docetaxel 8 pembrolizumab 7 Pemetrexed 5 Carboplatin 5 Erlotinib Hydrochloride 4 toripalimab 3 rociletinib 3 Radiosurgery 3 Oxaliplatin 3 Nivolumab 3 Gemcitabine 3 Etoposide 3 Cisplatin 3 Bevacizumab 3 lorlatinib 2 fludarabine 2 atezolizumab 2 Vinorelbine 2 Topotecan 2 Radiotherapy 2 Platinum 2 Paclitaxel 2 Itraconazole 2 Irinotecan 2 Interleukin-2 2 Cyclophosphamide 2 Cetuximab 2 vinflunine 1 vandetanib 1 talazoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡